William Young (Thomas Jefferson University, Philadelphia, USA) discusses the most important developments in migraine prevention and treatment, and his roles as Past President of the Alliance for Headache Disorders Advocacy and President of Miles For Migraine.
1. What do you consider the most important developments in migraine prevention and treatment in the last year? (0:04)
2. What is a Chiari malformation headache and how can it be recognized? (0:45)
3. What is your opinion on the use of cannabinoids in the treatment of migraine? (1:44)
4. Could you tell us a little about your role as Past President of the Alliance for Headache Disorders Advocacy and President of Miles For Migraine? (2:25)
5. How can our choice of words improve understanding and empathy for people with migraine? (3:41)
Speaker disclosure: William Young has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Headache Disorders
Robert Music, The Migraine Trust: Improving migraine care – ensuring patient-focussed diagnosis and treatment in the UK
“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The […]
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!